Annals of the Rheumatic Diseases

Papers
(The H4-Index of Annals of the Rheumatic Diseases is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia951
Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumat584
Short duration antibiotic therapy for native joint arthritis caused by Neisseria infection?536
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al446
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19343
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al327
Dysregulation of immune checkpoint molecules as a characteristic of autoimmune congenital heart block327
POS0993 ELEVATED INTRACELLULAR IFN SIGNALING BY T AND B CELLS BUT UNALTERED B CELL DISTRIBUTION IS A CHARACTERISTIC OF ANTI-SSA POSITIVE ASYMPTOMATIC WOMEN AT-RISK FOR CONGENITAL HEART BLOCK313
POS0532 DEUCRAVACITINIB, AN ORAL, ALLOSTERIC, TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT-REPORTED OUTCOMES IN A PHASE 2 TRIAL309
OP0057 EVALUATION OF SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) COHORT306
AB0372 PAIN SYNDROME, PHYSICAL ACTIVITY AND QUALITY OF LIFE IN WOMEN WITH OSTEOARTHRITIS AND SARCOPENIA262
POS0389 LOW INCIDENCE OF LATE-ONSET GCA DURING THE FIRST YEAR IN PATIENTS WITH POLYMYALGIA RHEUMATICA — AN IMAGING-BASED STUDY262
POS1021 THE EFFECT OF CANNABIDIOL ON QUANTITATIVE SENSORY TESTING PARAMETERS IN PATIENTS WITH HAND OSTEOARTHRITIS AND PSORIATIC ARTHRITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL238
POS1430 WATCH OUT FOR THE INFLAMMATORY RESPONSE IN AUTOIMMUNE DISEASES WITH INTERSTITIAL PNEUMONIA. A RETROSPECTIVE STUDY237
POS0916 DRUG SURVIVAL OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: DATA FROM FIVE COUNTRIES OF LATIN AMERICA232
POS1035 FORCED VITAL CAPACITY TRAJECTORIES AND RISK OF LUNG TRANSPLANT AND ILD-RELATED MORTALITY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE220
POS1478-HPR ANALYSIS OF MEDICATION USAGE AND MONTHLY COSTS IN HOSPITALIZED PATIENTS WITH RHEUMATIC DISEASES: A RETROSPECTIVE OBSERVATIONAL STUDY218
AB0503 SELF-REPORTED CLINICAL AND PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE: RESULTS FROM THE BRAGGSS COHORT218
AB0738 EXPRESSION AND ROLE OF THE LNCRNA RP11-184M15.1 IN THE MYELOID COMPARTMENT DURING INFLAMMATION206
AB0183 CARDIAC EFFECTS OF THE ARTHRITIS/HEART FAILURE COMORBIDITY201
AB1016 SERUM CXCL-13 LEVELS ARE ASSOCIATED WITH ACTIVE NEUROLOGICAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS196
AB1151 CIRCULATING CTHRC1 LEVELS ARE ASSOCIATED WITH DISEASE SEVERITY AND PREDICT SURVIVAL IN SYSTEMIC SCLEROSIS193
AB1598-HPR MOTHERHOOD AND FAMILY PLANNING BELIEFS IN WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES173
AB1649-PARE BARRIERS TO DIAGNOSIS, TREATMENT, AND CARE FOR IgG4-RELATED DISEASE: DATA FROM A LARGE COHORT OF ITALIAN PATIENTS170
OP0120 EFFECTIVENESS AND COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPONDYLOARTHRITIS (TeleSpA-STUDY): A PRAGMATIC MULTICENTRE RANDOMISED CONTROLLED 169
AB0661 TOFACITINIB PLUS IGURATIMOD IN RHEUMATOID ARTHRITIS-RELATED PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE: 13 CASES FROM A SINGLE CENTRE IN CHINA167
AB0462 ONE-YEAR RETENTION RATE OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS. DATA OF THE SPANISH BIOBADASER REGISTRY166
AB0943 ASSESSING THE IMPACT OF SARCOPENIA IN AXIAL SPONDYLOARTHRITIS162
AB0916 EFFECTIVENESS OF A PERSONALIZED PHYSICAL TRAINING PROGRAM ON DISEASE ACTIVITY AND AEROBIC CAPACITY IN axSpA: A RANDOMIZED CONTROLLED STUDY154
AB0666 CYCLING VERSUS SWITCHING AFTER INEFFECTIVENESS OF FIRST TUMOR NECROSIS FACTOR INHIBITOR DURING FIRST YEAR OF THERAPY - DEMOGRAPHIC AND CLINICAL DIFFERENCES IN RHEUMATOID ARTHRITIS154
OP0251 DURATION OF CLINICALLY MEANINGFUL ANALGESIC RESPONSE TO INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE, EMPTY, MULTILAMELLAR LIPOSOMES, IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS: ANALYSI147
AB1258 EFFECTIVENESS OF DUPILUMAB ON REFRACTORY CHRONIC RHINOSINUSITIS WITH NASAL POLYPS IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A CLINICAL AND CYTOLOGICAL STUDY144
AB0732 CELLULAR AND MOLECULAR HALLMARKS OF EARLY METHOTREXATE RESPONSE IN RA143
POS0283 DISEASE - CHARACTERISTIC CHANGES CAN ALREADY BE FOUND IN INDIVIDUALS AT RISK OF SJÖGREN’S SYNDROME – RESULTS OF THE preSStige STUDY140
POS0071 IMMUNOMODULATORY TREATMENT AND IMMUNE RESPONSES TO COVID-19 BOOSTER SHOTS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINE RESPONSE IN RHEUMATOLOGY PATIENTS (C140
POS0344 PAROTID TRANSCRIPTOMIC NETWORKS ASSOCIATED WITH B CELL HYPERACTIVITY, AND VIRUS/IFN ACTIVITY ARE TARGETED BY LEFLUNOMIDE/HYDROXYCHLOROQUINE THERAPY IN SJÖGREN PATIENTS AND ARE CAPTURED BY A CI137
AB0394 COMORBIDITIES IN 40.643 PSORIATIC ARTHRITIS PATIENTS ACCORDING TO GENDER: RESULTS FROM E.PULSE, THE NATIONWIDE HEALTH DATA134
POS1001 INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS ALLEVIATE SJÖGREN’S SYNDROME BY MODULATING THE MATURATION PROCESS OF SPLENIC B CELLS133
POS0743 OPTIMIZING REFERRAL TO RHEUMATOLOGY – A NEW STRATEGY TO PREVENT REFERRAL OF PATIENTS WITH LOW LIKELIHOOD OF AN INFLAMMATORY RHEUMATIC DISEASE131
AB0160 THE USE OF IL-6 INHIBITORS IN PATIENTS WITH POLYMYALGIA RHEUMATICA RECEIVING GLUCOCORTICOID THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS124
AB1272 MANAGING OF ANCA-ASSOCIATED VASCULITIS: ADHERENCE TO TREATMENT GUIDELINES AND EARLY MODIFICATIONS, ARE WE THERE YET?121
POS0234 IMPACT OF PROPHYLACTIC TRIMETHOPRIM-SULFAMETHOXAZOLE ON THE INCIDENCE OF SERIOUS INFECTION IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS: A MULTICENTER COHORT STUDY117
POS0878 INFERTILITY AND THE CHANCE OF SUCCESSFUL ASSISTED REPRODUCTION TREATMENTS IN CHILDBEARING WOMEN WITH RHEUMATIC DISEASES115
AB0073 ANTIBODY RESPONSE AND COVID-19 DISEASE AFTER SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES RECEIVING BIOLOGICAL TREATMENT112
POS0349 SINGLE OSTEOCLAST RESORPTION ANALYSIS REVEALS AN INCREASED INTRINSIC OSTEOCLAST ACTIVITY IN RA PATIENTS111
POS1220 MODULATING INFLAMMATION IN AN ADVANCED 3D MODEL OF RHEUMATOID ARTHRITIS SYNOVIAL TISSUE INCORPORATING FIBROBLASTS, ENDOTHELIAL CELLS AND MACROPHAGES110
AB1331 DIAGNOSTIC CAPABILITY OF ANESTHETIC INTRA-ARTICULAR INJECTIONS FOR FEMOROACETABULAR IMPINGEMENT108
AB1349 CORRELATION OF CHRONIC INFLAMMATION MARKERS WITH ULTRASOUND SIGNS OF ATHEROSCLEROTIC HEART DISEASE AND BRACHIOCEPHALIC ARTERIES LESIONS IN RHEUMATOID ARTHRITIS107
AB1019 THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJECTS ON INFLAMMATORY CYTOKINES – A RANDOMISED OPEN-LABEL PARALLEL GROUPS STUDY106
AB0795 Are patients with ankylosing spondylitis afraid of falling compared to healthy controls?: the role of balance and posture104
AB0928 CHARACTERISTICS OF AXIAL PSORIATIC ARTHRITIS PATIENTS WITH SYMMETRICAL AND ASYMMETRICAL SACROILIITIS101
AB1025 TRABECULAR BONE SCORE IN PATIENTS WITH AXIAL-SPONDYLOARTHRITIS99
AB0311 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS: FREQUENCY AND ASSOCIATED FACTORS99
AB0777 Influence of TNF inhibitors on subclinical atherosclerosis in Spondyloarthritis patients99
AB1134 BIBLIOMETRIC NETWORK ANALYSIS ON TOCILIZUMAB TREATMENT FOR COVID-19 PATIENTS97
AB1127 ANTIOSTEOPOROTIC TREATMENT AND COVID-19 RISK: IS THERE AN ASSOCIATION?97
AB0345 THERAPEUTIC DRUG LEVELS TO ACHIEVE GOOD EULAR RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB: RESULTS FROM THE BIOLOGICS IN RHEUMATOID ARTHRITIS GENETICS AND GENOMICS STUDY95
AB0878 Higher vitamin D serum level is associated with a better clinical response to bDMARDs in patients with axial spondyloarthritis.94
POS1566-PARE BEYOND MEDICATION – SELF MANAGEMENT AS A COMPLEMENTARY APPROACH FOR TREATING RMDS93
POS1526-HPR WHICH FACTORS INFLUENCE PATIENTS' PREFERENCES FOR TELEHEALTH APPLICATIONS IN RHEUMATIC DISEASES? A QUALITATIVE STUDY91
OP0128 ADHERENCE TO MEDICATIONS DURING PREGNANCY IN SYSTEMIC AUTOIMMUNE DISEASE90
POS0740 IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS90
POS0851 FREQUENCY OF METABOLIC SYNDROME AND ITS RELATIONSHIP WITH DISEASE CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS89
POS0959 IMPACT OF INITIATION OF TARGETED THERAPY ON THE USE OF ASSOCIATED TREATMENTS AND HEALTHCARE CONSUMPTION IN PSORIATIC ARTHRITIS: A COHORT STUDY OF 9,793 PATIENTS FROM THE FRENCH HEALTH INSURANC88
POS1216 NIEMANN-PICK PROTEINS TYPE C2 DRIVES PROINFLAMMATORY PROPERTIES OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS THROUGH MEDIATING CHOLESTEROL METABOLIC REPROGRAMMING87
AB1553-HPR BASELINE CHARACTERISTICS OF PATIENTS WITH SLE ACROSS 5 REGISTRIES – THE LUPUSNET FEDERATED DATA NETWORK85
POS0115 EOSINOPHILIC GIANT CELL ARTERITIS: A DIFFERENT SUBSET OF DISEASE?85
AB0251 CLINICAL FEATURES OF KOREAN PATIENTS WITH ANTI-SRP ANTIBODY-ASSOCIATED IMMUNE-MEDIATED NECROTIZING MYOPATHY82
POS1107 IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF 2 DOSES OF AN ADJUVANTED HERPES ZOSTER SUBUNIT VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RANDOMIZED CLINICAL TRIAL82
POS0813 PREDICTORS OF RESPONSE TO bDMARDs AND tsDMARDs THERAPY: THE ROLE OF MUSCULOSKELETAL ULTRASOUND AND POTENTIAL NEW BIOMARKERS81
AB1320 DOPPLER ULTRASOUND IN GIANT CELL ARTERITIS: WHICH TERRITORIES SHOULD WE EXPLORE? A RETROSPECTIVE ANALYSIS OF A SINGLE CENTER EXPERIENCE80
AB0482 PREVALENCE AND SEVERITY OF MAFLD IN PSORIATIC DISEASE: ARE WE MISSING SOMETHING?80
AB0529 JAK-INHIBITORS PROMOTE INSULIN SENSITIVITY AND ENHANCE IMMUNOSUPPRESSIVE EFFECT OF INSULIN ON CD4+ T CELLS OF PATIENTS WITH RHEUMATOID ARTHRITIS79
POS1108 SUBCLINICAL ATHEROSCLEROSIS IS ASSOCIATED WITH FUTURE CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AT APPARENT LOW RISK FOR CARDIOVASCULAR DISEASE: A LONGITUDINAL PROSPECTIVE79
AB1323 ALL WALES GCA AUDIT 2023-A QUALITY IMPROVEMENT INITIATIVE TO IMPROVE GCA CARE ACROSS WALES79
AB1535 A PROFILE OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (SARD-PAH) FROM WESTERN INDIA: A SINGLE CENTRE RETROSPECTIVE STUDY78
AB0393 MUSCULOSKELETAL MANIFESTATIONS IN PATIENTS DIAGNOSED WITH MARFAN SYNDROME77
AB0102 DIFFERENTIAL EXPRESSION OF ORTHOLOGUE GENES INVOLVED IN GLYCINE AND PYRUVATE METABOLISM CHARACTERIZE THE GUT MICROBIOME META-TRANSCRIPTOME OF SUBJECTS WITH ASYMPTOMATIC HYPERURICEMIA AND GOUT77
POS0866 LARGE-VESSEL INVOLVEMENT IN ANCA-ASSOCIATED VASCULITIS: A MULTICENTER CASE-CONTROL STUDY77
POS0118-PARE THE RAIISE SCHOOL PACK FOR TEACHERS SUPPORTING CHILDREN AND YOUNG PEOPLE WITH INVISIBLE ILLNESSES IN SCHOOL: A MULTI-STAKEHOLDER CO-CREATION PROCESS77
AB0445 EVALUATION OF SUBCLINICAL BOWEL INFLAMMATION USING FAECAL CALPROTECTIN LEVEL IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS – A PILOT STUDY77
POS0449 GENE THERAPY WITH INTERFERENCE miRNAs AS A NEW ALTERNATIVE FOR DISCOID CUTANEOUS LUPUS (DLE)77
0.028847217559814